2238 Aplin, Andrew E. - Thomas Jefferson University - Thomas Jefferson University
aea004

Andrew E. Aplin, PhD

Contact Dr. Aplin

Kimmel Cancer Center
233 S. Tenth Street, Suite 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Animal experimentation - questioned again!
  2. The value of thesis advisers
  3. What shall we do this year?
  4. Game of isoforms: PI3K β-sparing inhibitor is coming
  5. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells
  6. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor
  7. Resistance to RAF inhibitors revisited
  8. FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma
  9. Unmet needs in melanoma research
  10. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma
  11. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors
  12. Erratum: Hippo: Hungry, hungry for melanoma invasion (Journal of Investigative Dermatology)
  13. Hippo: Hungry, hungry for melanoma invasion
  14. Adaptive resistance to RAF inhibitors in melanoma
  15. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma
  16. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors
  17. A statement on vemurafenib-resistant melanoma
  18. Meeting report: The fu 0465 ture of preclinical mouse models in melanoma treatment is now.
  19. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
  20. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
0